159 related articles for article (PubMed ID: 28787735)
41. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease.
Solla P; Cannas A; Ibba FC; Loi F; Corona M; Orofino G; Marrosu MG; Marrosu F
J Neurol Sci; 2012 Dec; 323(1-2):33-9. PubMed ID: 22935408
[TBL] [Abstract][Full Text] [Related]
42. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study.
Fuchs T; Trollor JN; Crawford J; Brown DA; Baune BT; Samaras K; Campbell L; Breit SN; Brodaty H; Sachdev P; Smith E
Aging Cell; 2013 Oct; 12(5):882-9. PubMed ID: 23758647
[TBL] [Abstract][Full Text] [Related]
43. The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.
Vieru E; Köksal A; Mutluay B; Dirican AC; Altunkaynak Y; Baybas S
Neurol Sci; 2016 May; 37(5):743-7. PubMed ID: 26753800
[TBL] [Abstract][Full Text] [Related]
44. Acute stepwise challenge test with levodopa in treated patients with parkinsonism.
Feng T; Li W; Lu L; Wang Y; Shi W; Zhang J; Wang Y; Chan P
Parkinsonism Relat Disord; 2009 Jun; 15(5):354-8. PubMed ID: 19010079
[TBL] [Abstract][Full Text] [Related]
45. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
Winge K; Werdelin LM; Nielsen KK; Stimpel H
Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
[TBL] [Abstract][Full Text] [Related]
46. Elevated growth differentiation factor 15 levels predict outcome in patients undergoing transcatheter aortic valve implantation.
Krau NC; Lünstedt NS; Freitag-Wolf S; Brehm D; Petzina R; Lutter G; Bramlage P; Dempfle A; Frey N; Frank D
Eur J Heart Fail; 2015 Sep; 17(9):945-55. PubMed ID: 26230285
[TBL] [Abstract][Full Text] [Related]
47. Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-control study.
Rathnayake D; Chang T; Udagama P
BMC Neurol; 2019 Apr; 19(1):56. PubMed ID: 30954070
[TBL] [Abstract][Full Text] [Related]
48. Serum Butyrylcholinesterase Activity: A Biomarker for Parkinson's Disease and Related Dementia.
Dong MX; Xu XM; Hu L; Liu Y; Huang YJ; Wei YD
Biomed Res Int; 2017; 2017():1524107. PubMed ID: 28840123
[TBL] [Abstract][Full Text] [Related]
49. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
[TBL] [Abstract][Full Text] [Related]
50. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
[TBL] [Abstract][Full Text] [Related]
51. Growth Differentiation Factor-15 and Clinical Outcomes in Lower Extremity Artery Disease.
Shikama T; Otaki Y; Watanabe T; Tamura H; Kato S; Nishiyama S; Takahashi H; Arimoto T; Watanabe M
J Atheroscler Thromb; 2024 Jun; 31(6):964-978. PubMed ID: 38296521
[TBL] [Abstract][Full Text] [Related]
52. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
[TBL] [Abstract][Full Text] [Related]
53. UPDRS activity of daily living score as a marker of Parkinson's disease progression.
Harrison MB; Wylie SA; Frysinger RC; Patrie JT; Huss DS; Currie LJ; Wooten GF
Mov Disord; 2009 Jan; 24(2):224-30. PubMed ID: 18951537
[TBL] [Abstract][Full Text] [Related]
54. Serum levels of GDF15 are reduced in preeclampsia and the reduction is more profound in late-onset than early-onset cases.
Chen Q; Wang Y; Zhao M; Hyett J; da Silva Costa F; Nie G
Cytokine; 2016 Jul; 83():226-230. PubMed ID: 27173615
[TBL] [Abstract][Full Text] [Related]
55. GDF15 is related to anemia and hepcidin in kidney allograft recipients.
Malyszko J; Koc-Zorawska E; Malyszko JS; Glowinska I; Mysliwiec M; Macdougall IC
Nephron Clin Pract; 2013; 123(1-2):112-7. PubMed ID: 23797049
[TBL] [Abstract][Full Text] [Related]
56. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
Bachmann CG; Zapf A; Brunner E; Trenkwalder C
Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
[TBL] [Abstract][Full Text] [Related]
57. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
Martinelli P; Contin M; Scaglione C; Riva R; Albani F; Baruzzi A
Neurol Sci; 2003 Oct; 24(3):192-3. PubMed ID: 14598082
[TBL] [Abstract][Full Text] [Related]
58. Increased Serum Level of Growth Differentiation Factor 15 (GDF-15) is Associated with Coronary Artery Disease.
Wang X; Chen LL; Zhang Q
Cardiovasc Ther; 2016 Jun; 34(3):138-43. PubMed ID: 26996787
[TBL] [Abstract][Full Text] [Related]
59. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
60. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
Cubo E; González M; Aguilar A; Quintana S
Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
